Dexmedetomidine for the treatment of alcohol withdrawal syndrome: Rationale and current status of research

CNS Drugs

Volumn 27, Issue 11, 2013, Pages 913-920

  Muzyk, Andrew J ^a,b   Kerns, Suzanne ^b   Brudney, Scott ^c   Gagliardi, Jane P ^b  

^a Campbell University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE; CLONIDINE; DEXMEDETOMIDINE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; OXAZEPAM; PLACEBO; PROPOFOL; PROPRANOLOL;

ADJUVANT THERAPY; AGITATION; ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ARTIFICIAL VENTILATION; BLOOD PRESSURE; BRADYCARDIA; DAY HOSPITAL; DELIRIUM; DIAPHORESIS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERACTIVITY; HYPOTENSION; INTENSIVE CARE UNIT; IRRITABILITY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; NONHUMAN; NORADRENERGIC SYSTEM; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY FAILURE; REVIEW; RIGIDITY; SEDATION; SEIZURE; SIDE EFFECT; TACHYCARDIA; TREMOR; VISUAL HALLUCINATION;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; BIOMEDICAL RESEARCH; DEXMEDETOMIDINE; ETHANOL; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84887059605     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0106-6     Document Type: Review

References (47)

1. McKeon A, Frye M, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2007;79:854-62.
2. de Wit M, Jones DG, Sessler CN, Zilberberg MD, Weaver MF. Alcohol-use disorders in the critically ill patient. Chest. 2010;138:994-1003.
3. Genther D, Gourin C. The effect of alcohol abuse and alcohol withdrawal on short-term outcomes and cost of care after head and neck cancer surgery. Laryngoscope. 2012;122:1739-47.
4. Awissi D, Lebrun G, Coursin DB, Riker RR, Skrobik Y. Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med. 2013;39:16-30.
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
6. Monte R, Rabunal R, Casariego E. Risk factors for delirium tremens in patients with alcohol withdrawal syndrome in a hospital setting. Eur J Intern Med. 2009;20:690-4.
7. Stern TA. Alcohol-induced disorders. In: Stern TA, Rosenbaum JF, Fava M, editors. Massachusetts general hospital comprehensive clinical psychiatry, vol. 1. New York: Mosby/Elsevier; 2008. p. 1059-60.
8. McKeon A, Frye M, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2008;79:854-61.
9. Hall W, Zador D. The alcohol withdrawal syndrome. Lancet. 1997;349:1897-900.
10. Borg S, Kvande H, Sedvall G. Central norepinephrine metabolism during alcohol intoxication in addicts and health volunteers. Science. 1981;213:1137.
11. Linnoila M, Mefford I, Nutt D, Adinoff B. NIH conference. Alcohol withdrawal and noradrenergic function. Ann Intern Med. 1987;107:879.
12. Mayo-Smith M, Beecher L, Fischer T, Gorelick D, Guillaume J, Jara G, Kasser C, Melbourne J. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004;164:1405-12.
13. Mayo-Smith. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management. JAMA. 1997;278(2):144-51.
14. Manasco A, Chang S, Larriviere J, Hamm LL, Glass M. Alcohol withdrawal. South Med J. 2012;105(11):607-12.
15. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev. 2011;(6):CD008537.
16. Rayner SG, Weinert CR, Peng H, Jepsen S, Broccard AF. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(12):1-6.
17. Tolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med. 2012. doi: 10.1097/MEJ.0b013e32835c53b3.
18. Muzyk AJ, Fowler JA, Norwood DK, Chilipko A. Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother. 2011;45(5):649-57.
19. Rovasalo A, Tohmo H, Aantaa R, Kettunen E, Palojoki R. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006;28(4):362-3.
20. Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42(11):1703-5.
21. Tang JF, Chen PL, Tang EJ, May TA, Stiver SI. Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury. Neurocrit Care. 2011;15(1):175-81.
22. DeMuro JP, Botros DG, Wirkowski E, Hanna AF. Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series. J Anesth. 2012;26(4):601-5.
23. Muzyk AJ, Revollo JY, Rivelli SK. The use of dexmedetomidine in alcohol withdrawal. J Neuropsychiatry Clin Neurosci. 2012;24(3):E45-6.
24. Jaatinen P, Riihioja P, Haapalinna A, Heinonen E, Kiianmaa K, Hervonen A. Prevention of ethanol-induced sympathetic overactivity and degeneration by dexmedetomidine. Alcohol. 1995;12(5):439-46.
25. Riihioja P, Jaatinen P, Oksanen H, Haapalinna A, Heinonen E, Hervonen A. Dexmedetomidine, diazepam, and propranolol in the treatment of ethanol withdrawal symptoms in the rat. Alcohol Clin Exp Res. 1997;21(5):804-8.
26. Riihioja P, Jaatinen P, Oksanen H, Haapalinna A, Heinonen E, Hervonen A. Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat. Alcohol. 1997;14(6):537-44.
27. Precedex [package insert]. Lake Forest (IL): Hospira, Inc., 2010.
28. Szumita PM, Baroletti SA, Anger KE, Wechsler ME. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm. 2007;16:37-44.
29. Bamgbade OA. Dexmedetomidine for peri-operative sedation and analgesia in alcohol addiction. Anaesthesia. 2006;61(3):299-300.
30. Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98(2):575-7.
31. Heinz A, Schmidt K, Baum SS, et al. Influence of dopaminergic transmission on severity of withdrawal syndrome in alcoholism. J Stud Alcohol. 1996;57:471-4.
32. Krystal JH, Tabakoff B. Ethanol abuse, dependence and withdrawal: neurobiology and clinical implications. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: 5th generation of progress. New York: Lippincott Williams and Wilkins; 2002. p. 1425-43.
33. Myrick H, Anton RF. Treatment of alcohol withdrawal. Alcohol Health Res World. 1998;22:38-43.
34. Hawley RJ, Nemeroff CB, Bissette G, et al. Neurochemical correlates of sympathetic activation during severe alcohol withdrawal. Alcohol Clin Exp Res. 1994;18:1312-6.
35. Walker BM, Rasmussen DD, Raskind MA, Koob GF. Alpha-1 noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol. 2008;42:91-7.
36. Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, et al. Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. Alcohol. 2003;38:224-31.
37. Riihioja P, Jaatinen P, Haapalinna A, Kiianmaa K, Hervonen A. Effects of dexmedetomidine on rat locus coeruleus and ethanol withdrawal symptoms during intermittent ethanol exposure. Alcohol Clin Exp Res. 1999;23(3):432-8.
38. Hoy S, Keating G. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481-501.
39. Gerlach A, Murphy C, Dasta J. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43:2064-74.
40. Johnson MT, Yamanaka TT, Fraidenburg DR, Kane SP. Benzodiazepine misadventure in acute alcohol withdrawal: the transition from delirium tremens to ICU delirium. J Anesth. 2013;27(1):135-6.
41. Bayard M, Mcintyre J, Hill K, Woodside J. Alcohol withdrawal syndrome. Am Fam Physician. 2004;69(6):1443-50.
42. Gerlach AT, Dasta JF, Steinberg S, Martin LC, Cook CH. A new dosing protocol reduces dexmedetomidine hypotension in critically ill surgical patients. J Crit Care. 2009;24(4):568-74.
43. Maclaren R, Krisl JC, Cochrane RE, Mueller SW. A case-based approach to the practical application of dexmedetomidine in critically ill adults. Pharmacotherapy. 2013;33(2):165-86.
44. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30:2188-96.
45. Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, Shepherd ST, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009;35:282-90.
46. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs haloperidol in delirious, agitated, intubated patients: a randomized open-label trial. Critical Care. 2009;13(3):R75.
47. Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit care. 2010;12(3):356-61.